Children's Oncology Group's 2023 blueprint for research: Central nervous system tumors
Pediatric Blood & Cancer · 2023
DOI: 10.1002/pbc.30600 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2023. Verfasst von Sarah E S Leary und 9 weiteren Autor:innen. Beteiligte Einrichtung: Ben Towne Center for Childhood Cancer Research, Seattle Children's Hospital, Seattle, Washington, USA. Hauptthemen laut MEDLINE: Central Nervous System Neoplasms, Glioma, Medulloblastoma, Cerebellar Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIH HHS, National Institutes of Health.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Tumors of the central nervous system (CNS) are a leading cause of morbidity and mortality in the pediatric population. Molecular characterization in the last decade has redefined CNS tumor diagnoses and risk stratification; confirmed the unique biology of pediatric tumors as distinct entities from tumors that occur in adulthood; and led to the first novel targeted therapies receiving Food and Drug Administration (FDA) approval for children with CNS tumors. There remain significant challenges to overcome: children with unresectable low‐grade glioma may require multiple prolonged courses of therapy affecting quality of life; children with high‐grade glioma have a dismal long‐term prognosis; children with medulloblastoma may suffer significant short‐ and long‐term morbidity from multimodal cytotoxic therapy, and approaches to improve survival in ependymoma remain elusive. The Children's Oncology Group (COG) is uniquely positioned to conduct the next generation of practice‐changing clinical trials through rapid prospective molecular characterization and therapy evaluation in well‐defined clinical and molecular groups.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Ben Towne Center for Childhood Cancer Research, Seattle Children's Hospital, Seattle, Washington, USA.
- Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
- Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta and Emory University School of Medicine, Atlanta, Georgia, USA.
- Telethon Kids Cancer Centre, University of Western Australia, Perth, Western Australia, Australia.
- The Sidney Kimmel Comprehensive Cancer Center, John's Hopkins, Baltimore, Maryland, USA.
- Division of Pediatric Hematology, Oncology and Bone Marrow Transplant, Orlando Health-Arnold Palmer Hospital, Orlando, Florida, USA.
ORCID-Profile: Sarah E S Leary
Förderung
- NCI NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Leary, S. E. S., Onar-Thomas, A., Fangusaro, J., Gottardo, N. G., Cohen, K., Smith, A., Huang, A., Haas-Kogan, D., Fouladi, M., & COG Central Nervous System Committee (2023). Children's Oncology Group's 2023 blueprint for research: Central nervous system tumors. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.30600
Vancouver
Leary SES, Onar-Thomas A, Fangusaro J, Gottardo NG, Cohen K, Smith A, et al. Children's Oncology Group's 2023 blueprint for research: Central nervous system tumors. Pediatric Blood & Cancer. 2023. doi:10.1002/pbc.30600
BibTeX
@article{Leary2023,
author = {Leary, Sarah E S and Onar-Thomas, Arzu and Fangusaro, Jason and Gottardo, Nicholas G and Cohen, Kenneth and Smith, Amy and Huang, Annie and Haas-Kogan, Daphne and Fouladi, Maryam and COG Central Nervous System Committee, COG Central Nervous System Committee},
title = {Children's Oncology Group's 2023 blueprint for research: Central nervous system tumors},
journal = {Pediatric Blood & Cancer},
year = {2023},
doi = {10.1002/pbc.30600}
}
EUVIMED